Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 214 participants.
Also called NCT05504226
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 214 participants
- Sponsor
- Registry
-
NCT05504226
-
- Other papers using this trial's data
- A 52-Week Efficacy and Safety Study of Teneligliptin, as an Add-On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial (TERA305 Study)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05504226. Randomized; quadruple masking; primary purpose treatment. Start 2022-10-12 (actual); primary completion 2023-11-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin
- Acronym
- TERA 305
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
- Intervention (Drug)
- Teneligliptin Placebo Oral Tablet
- Lead sponsor
- Handok Inc.
Record details
- Record id
cardio:ct-nct05504226- Content hash
123689da1f086c2fc1e9e75496d5f15ff05b47d3b46edd763bf9eb5dc46eaa6f